124 related articles for article (PubMed ID: 38606821)
1. Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience.
Wijaya ST; Ngoi NY; Loh JW; Tan TZ; Lim D; Khan IS; Thian YL; Lai A; Ang BW; Tong P; Ng J; Low JJ; Ilancheran A; Lim SE; Lim YW; Tan DS
J Gynecol Oncol; 2024 Mar; ():. PubMed ID: 38606821
[TBL] [Abstract][Full Text] [Related]
2. Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
Kim SI; Kim JH; Noh JJ; Kim SH; Kim TE; Kim K; Park JY; Lim MC; Lee JW; Kim JW
Gynecol Oncol; 2022 Sep; 166(3):444-452. PubMed ID: 35863991
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with
Li S; Zhang J; Du W; Ren X; Zhang X
Gland Surg; 2022 Sep; 11(9):1562-1567. PubMed ID: 36221285
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
[TBL] [Abstract][Full Text] [Related]
7. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
8. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial.
Li R; Liu X; Song C; Zhang W; Liu J; Jiao X; Yu Y; Zeng S; Chi J; Zhao Y; Ma G; Huo Y; Li M; Peng Z; Li G; Jiang J; Gao QL
BMJ Open; 2022 May; 12(5):e058132. PubMed ID: 35613822
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
13. Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study.
Kim SI; Lim H; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Lee M
Cancer Res Treat; 2023 Jan; 55(1):245-257. PubMed ID: 35879854
[TBL] [Abstract][Full Text] [Related]
14. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
[TBL] [Abstract][Full Text] [Related]
15. Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort.
Sun M; Jiang W
Discov Oncol; 2023 Apr; 14(1):39. PubMed ID: 37004660
[TBL] [Abstract][Full Text] [Related]
16. Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.
Zhao Y; Jiang Y
Onco Targets Ther; 2022; 15():323-328. PubMed ID: 35401005
[TBL] [Abstract][Full Text] [Related]
17. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series.
Glynn SM; Gaillard S; Stone RL; Fader AN; Beavis AL
Gynecol Oncol Rep; 2024 Jun; 53():101374. PubMed ID: 38633673
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
20. Secondary cytoreduction in platinum sensitive relapsed ovarian cancer: an individual patient level meta-analysis.
Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
Int J Gynecol Cancer; 2023 Sep; 33(9):1440-1447. PubMed ID: 37567595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
